Background: : Continuous glucose monitors (CGMs) intersect evolving technology with clinical science to provide real-time, continuous data on glucose trends rather than isolated point-in-time readings. By offering dynamic insights into glucose fluctuations throughout the day and night, CGMs enable more proactive and personalized diabetes management. CGM use has been associated with improved A1c levels, reduced hypoglycemic events, and decreased time spent in hyperglycemic episodes. The American Diabetes Association’s 2025 guidelines have expanded CGM recommendations to include both adults and youth on any insulin regimen, as well as adults with type 2 diabetes using any glucose-lowering therapy, to help achieve and maintain glycemic targets. This study aims to evaluate how CGMs have impacted healthcare resource utilization and total costs across the pharmacy and medical benefit, particularly within diverse patient populations and across varying therapy regimens.
Objective: : To determine whether the use of CGMs is associated with reduced pharmacy and medical benefit costs in patients with diabetes, regardless of therapy intensity
Methods: : A retrospective analysis will be conducted using pharmacy and medical claims data from January 1, 2023, to December 31, 2024. The metrics evaluated include, but are not limited to:
